<?xml version="1.0" encoding="UTF-8" ?><!-- Generated on Thu, 09 Apr 2026 17:51:47 -0400--><rss version="2.0">
    <channel>
        <title>Rigel Pharmaceuticals, Inc. (RIGL) Press Releases</title>
        <link>https://www.rigel.com/news-media/press-releases/rss</link>
        <description></description>
        <language>en-us</language>
                                            <image>
                <url>https://d1io3yog0oux5.cloudfront.net/rigel/files/rigel-logo-color-R_%281%29.png</url>
                <title>Rigel Pharmaceuticals, Inc. Logo</title>
                <link>https://www.rigel.com</link>
            </image>
                <generator>Equisolve Investor Relations Suite</generator>
        
                            <item>
                <title><![CDATA[Rigel Announces Publication of Final ARROW Clinical Trial Data on GAVRETO® (pralsetinib) in Patients with RET+ NSCLC in the Journal of Clinical Oncology]]></title>
                <description><![CDATA[]]></description>
                <link>https://www.rigel.com/news-media/press-releases/detail/434/rigel-announces-publication-of-final-arrow-clinical-trial</link>
                <pubDate>Tue, 31 Mar 26 08:05:00 -0400</pubDate>
                <guid isPermalink="true">https://www.rigel.com/news-media/press-releases/detail/434/rigel-announces-publication-of-final-arrow-clinical-trial</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[Rigel Provides Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update]]></title>
                <description><![CDATA[]]></description>
                <link>https://www.rigel.com/news-media/press-releases/detail/433/rigel-provides-fourth-quarter-and-full-year-2025-financial</link>
                <pubDate>Tue, 03 Mar 26 16:01:00 -0500</pubDate>
                <guid isPermalink="true">https://www.rigel.com/news-media/press-releases/detail/433/rigel-provides-fourth-quarter-and-full-year-2025-financial</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2025 Financial Results and Business Update]]></title>
                <description><![CDATA[]]></description>
                <link>https://www.rigel.com/news-media/press-releases/detail/432/rigel-announces-conference-call-and-webcast-to-report</link>
                <pubDate>Tue, 24 Feb 26 08:05:00 -0500</pubDate>
                <guid isPermalink="true">https://www.rigel.com/news-media/press-releases/detail/432/rigel-announces-conference-call-and-webcast-to-report</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[Rigel Appoints Michael P. Miller to the Board of Directors]]></title>
                <description><![CDATA[]]></description>
                <link>https://www.rigel.com/news-media/press-releases/detail/431/rigel-appoints-michael-p-miller-to-the-board-of-directors</link>
                <pubDate>Tue, 03 Feb 26 08:05:00 -0500</pubDate>
                <guid isPermalink="true">https://www.rigel.com/news-media/press-releases/detail/431/rigel-appoints-michael-p-miller-to-the-board-of-directors</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[Rigel Provides Business Update and 2026 Outlook]]></title>
                <description><![CDATA[]]></description>
                <link>https://www.rigel.com/news-media/press-releases/detail/430/rigel-provides-business-update-and-2026-outlook</link>
                <pubDate>Mon, 12 Jan 26 08:05:00 -0500</pubDate>
                <guid isPermalink="true">https://www.rigel.com/news-media/press-releases/detail/430/rigel-provides-business-update-and-2026-outlook</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)]]></title>
                <description><![CDATA[]]></description>
                <link>https://www.rigel.com/news-media/press-releases/detail/429/rigel-pharmaceuticals-inc-announces-inducement-grants</link>
                <pubDate>Fri, 09 Jan 26 08:05:00 -0500</pubDate>
                <guid isPermalink="true">https://www.rigel.com/news-media/press-releases/detail/429/rigel-pharmaceuticals-inc-announces-inducement-grants</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[Rigel to Present at the 44th Annual J.P. Morgan Healthcare Conference]]></title>
                <description><![CDATA[]]></description>
                <link>https://www.rigel.com/news-media/press-releases/detail/428/rigel-to-present-at-the-44th-annual-j-p-morgan-healthcare</link>
                <pubDate>Wed, 07 Jan 26 08:05:00 -0500</pubDate>
                <guid isPermalink="true">https://www.rigel.com/news-media/press-releases/detail/428/rigel-to-present-at-the-44th-annual-j-p-morgan-healthcare</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[Rigel Presents Updated Data from the Ongoing Phase 1b Study Evaluating R289 in Patients with Lower-Risk MDS at the 67th ASH Annual Meeting and Exposition]]></title>
                <description><![CDATA[]]></description>
                <link>https://www.rigel.com/news-media/press-releases/detail/427/rigel-presents-updated-data-from-the-ongoing-phase-1b-study</link>
                <pubDate>Sun, 07 Dec 25 09:30:00 -0500</pubDate>
                <guid isPermalink="true">https://www.rigel.com/news-media/press-releases/detail/427/rigel-presents-updated-data-from-the-ongoing-phase-1b-study</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[Rigel to Present at the Piper Sandler 37th Annual Healthcare Conference]]></title>
                <description><![CDATA[]]></description>
                <link>https://www.rigel.com/news-media/press-releases/detail/426/rigel-to-present-at-the-piper-sandler-37th-annual</link>
                <pubDate>Wed, 26 Nov 25 08:05:00 -0500</pubDate>
                <guid isPermalink="true">https://www.rigel.com/news-media/press-releases/detail/426/rigel-to-present-at-the-piper-sandler-37th-annual</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[Rigel Announces Publication of Final 5-year Data on REZLIDHIA® (olutasidenib) in Patients with R/R mIDH1 AML in the Journal of Hematology & Oncology]]></title>
                <description><![CDATA[]]></description>
                <link>https://www.rigel.com/news-media/press-releases/detail/425/rigel-announces-publication-of-final-5-year-data-on</link>
                <pubDate>Mon, 17 Nov 25 08:05:00 -0500</pubDate>
                <guid isPermalink="true">https://www.rigel.com/news-media/press-releases/detail/425/rigel-announces-publication-of-final-5-year-data-on</guid>
                                                                            </item>
            </channel>
</rss>